Table 1:
Hospital admission liver tests of 1827 patients with COVID-19
| Characteristic | Total (n=1827) | Non-severe COVID-19 (n=1175) | Severe COVID-19 (n=652) | p-value |
|---|---|---|---|---|
|
| ||||
| Age, mean (SD), years | 64.6 (18.2) | 63.4 (18.5) | 66.7 (17.5) | <0.001 |
|
| ||||
| Male gender, n (%) | 969 (53.0%) | 574 (48.9%) | 395 (60.6%) | <0.001 |
|
| ||||
| BMI, mean (SD) | 29.8 (7.8) | 29.2 (7.3) | 30.7 (8.5) | <0.001 |
|
| ||||
| Diabetes mellitus, n (%) | 712 (39.0%) | 412 (35.1%) | 300 (46.0%) | <0.001 |
|
| ||||
| Obesity, n (%) | 748 (42.5%) | 455 (40.4%) | 293 (46.1%) | 0.019 |
|
| ||||
| AST, median (range), U/L | 42 (8-3054) | 38 (8-1399) | 51 (12-3054) | <0.001 |
| AST abnormal (>33 U/L) | 1158 (66.9%) | 667 (60.7%) | 491 (77.8%) | <0.001 |
|
| ||||
| ALT, median (IQR), U/L | 29 (5-1831) | 28 (5-1831) | 31 (6-1441) | <0.001 |
| ALT, abnormal (>34 U/L) | 726 (41.6%) | 440 (39.7%) | 286 (44.8%) | 0.035 |
|
| ||||
| ALP, median (IQR), U/L | 76 (20-919) | 76 (20-903) | 76 (28-919) | 0.79 |
| ALP abnormal (>122 U/L) | 237 (13.5%) | 140 (12.6%) | 97 (15.2%) | 0.13 |
|
| ||||
| TBIL, median (IQR), mg/dL | 0.5 (0.1-8.9) | 0.4 (0.1-8.0) | 0.5 (0.1-8.9) | <0.001 |
| TBIL, abnormal (>1.2 mg/dL) | 74 (4.3%) | 33 (3.0%) | 41 (6.5%) | <0.001 |
|
| ||||
| Albumin, median (IQR) mg/dL | 3.5 (1.2-5.4) | 3.5 (1.3-5.4) | 3.3 (1.2-4.8) | <0.001 |
| Albumin, abnormal (<3.5 mg/dL) | 990 (56.7%) | 584 (52.6%) | 406 (63.8%) | <0.001 |
SD = standard deviation; BMI = body mass index; AST = aspartate aminotransferase; ALT = alanine aminotransferase; IQR = interquartile range; ALP = alkaline phosphatase; TBIL = total bilirubin
Severe COVID-19 defined as: death OR ICU stay OR use of mechanical ventilation OR vasopressor requirement, OR ECMO requirement.